The ongoing COVID-19 pandemic has resulted in millions of deaths globally, highlighting
the need to develop potent prophylactic and therapeutic strategies against SARS-CoV-2 …

This is the second of two invited articles reviewing the development of nucleoside analogue
antiviral drugs, written for a target audience of virologists and other non-chemists, as well as …

Azvudine (FNC) is a nucleoside analog that inhibits HIV-1 RNA-dependent RNA polymerase
(RdRp). Recently, we discovered FNC an agent against SARS-CoV-2, and have taken it into …

Twenty-five years ago, nucleoside analog 3′-azidothymidine (AZT) was shown to efficiently
block the replication of HIV in cell culture. Subsequent studies demonstrated that AZT acts …

HIV reverse transcriptase (RT) inhibitors are the important components of highly active
antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in …

Conspectus Modified nucleosides show therapeutic promise for antiviral therapies.
However, issues including the emergence of drug resistance, toxicity, and coinfections have …

Hepatitis C virus (HCV) infection is a global health problem that impacts approximately 180
million individuals. Of those initially infected with HCV approximately 80% will progress to …

Nucleoside analogs represent the largest class of small molecule-based antivirals, which
currently form the backbone of chemotherapy of chronic infections caused by HIV, hepatitis …

With Remdesivir being approved by FDA as a drug for the treatment of Corona Virus
Disease 2019 (COVID-19), nucleoside drugs have once again received widespread …

The development of safe and effective broad-spectrum antivirals that target the replication
machinery of respiratory viruses is of high priority in pandemic preparedness programs …